Suppr超能文献

神经肌肉疾病的基因治疗。

Gene-based therapies for neuromuscular disorders.

机构信息

Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil.

Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Neurologia, Campinas SP, Brazil.

出版信息

Arq Neuropsiquiatr. 2024 Jun;82(6):1-10. doi: 10.1055/s-0043-1777755. Epub 2024 Feb 7.

Abstract

Neuromuscular diseases (NMD) include a broad group of medical conditions with both acquired and genetic causes. In recent years, important advances have been made in the treatment of genetically caused NMD, and most of these advances are due to the implementation of therapies aimed at gene regulation. Among these therapies, gene replacement, small interfering RNA (siRNA), and antisense antinucleotides are the most promising approaches. More importantly, some of these therapies have already gained regulatory approval or are in the final stages of approval. The review focuses on motor neuron diseases, neuropathies, and Duchenne muscular dystrophy, summarizing the most recent developments in gene-based therapies for these conditions.

摘要

神经肌肉疾病(NMD)包括一组广泛的具有获得性和遗传性原因的医学病症。近年来,遗传性 NMD 的治疗取得了重要进展,而这些进展大多归因于针对基因调控的治疗方法的实施。在这些治疗方法中,基因替代、小干扰 RNA(siRNA)和反义抗核苷酸是最有前途的方法。更重要的是,其中一些治疗方法已经获得监管批准,或处于批准的最后阶段。本文综述主要集中在运动神经元疾病、神经病变和杜氏肌营养不良症,总结了针对这些疾病的基于基因的治疗方法的最新进展。

相似文献

1
Gene-based therapies for neuromuscular disorders.
Arq Neuropsiquiatr. 2024 Jun;82(6):1-10. doi: 10.1055/s-0043-1777755. Epub 2024 Feb 7.
3
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Molecules. 2017 Apr 5;22(4):563. doi: 10.3390/molecules22040563.
4
[Innovative therapeutic approaches for hereditary neuromuscular diseases].
Nervenarzt. 2018 Oct;89(10):1115-1122. doi: 10.1007/s00115-018-0599-9.
5
RNA-targeting approaches for neuromuscular diseases.
Trends Mol Med. 2009 Dec;15(12):580-91. doi: 10.1016/j.molmed.2009.10.005. Epub 2009 Nov 10.
6
RNA-targeted splice-correction therapy for neuromuscular disease.
Brain. 2010 Apr;133(Pt 4):957-72. doi: 10.1093/brain/awq002. Epub 2010 Feb 11.
7
[Molecular therapies: present and future in neuromuscular diseases].
Nervenarzt. 2023 Jun;94(6):473-487. doi: 10.1007/s00115-023-01495-3. Epub 2023 May 23.
8
Gene therapy for neuromuscular disorders: prospects and ethics.
Arch Dis Child. 2022 May;107(5):421-426. doi: 10.1136/archdischild-2020-320908. Epub 2021 Aug 30.
9
Gene and splicing therapies for neuromuscular diseases.
Front Biosci (Landmark Ed). 2015 Jun 1;20(8):1190-233. doi: 10.2741/4367.
10
New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Expert Opin Biol Ther. 2014 Jun;14(6):809-19. doi: 10.1517/14712598.2014.896335. Epub 2014 Mar 12.

本文引用的文献

1
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757.
2
Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy.
Front Neurol. 2023 Oct 5;14:1242815. doi: 10.3389/fneur.2023.1242815. eCollection 2023.
3
Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
Lancet Neurol. 2023 Nov;22(11):1061-1074. doi: 10.1016/S1474-4422(23)00334-4.
4
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688.
5
Advances in Dystrophinopathy Diagnosis and Therapy.
Biomolecules. 2023 Aug 28;13(9):1319. doi: 10.3390/biom13091319.
7
Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis.
Pharmacotherapy. 2024 Jan;44(1):97-105. doi: 10.1002/phar.2866. Epub 2023 Aug 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验